Cadila Healthcare - Zydus Lifesciences Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Cadila Healthcare - Zydus Lifesciences Share Price

1,105.6018.00 (1.66%)

Closed
As On: 09 Jun, 2026, 03:58 PM IST
As On: 09 Jun, 2026, 03:58 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	1,087.60
High	1,111.00
Low	1,085.50
Prev Close	1,087.60
Volume	12,99,872
VWAP(₹)	1,104.82

Key Metrics

PE Ratio(x)	22.07
EPS - TTM(₹)	50.09
MCap(₹ Cr.)	1,11,249
MCap Rank	4
PB Ratio(x)	3.70
Div Yield(%)	0.09
Face Value(₹)	1.00
52W High(₹)	1,115.50
52W Low(₹)	835.50
MCap/Sales	3.23
Beta(1 Month)	1.50
BV/Share(₹)	293.99

Cadila Healthcare share price insights

Rank 117 - ET 5002025 ranking

Dividend Announcement
Company announced a dividend of Rs 1.0 per share on May 19, 2026 with record date of Jul 24, 2026.
Employee & Interest Expense
Company has spent 1.62% of its operating revenues towards interest expenses and 16.27% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Decrease in Cash from Investing
Company has used Rs 8296.1 cr for investing activities which is an YoY decrease of 0.91%. (Source: Consolidated Financials)
Cadila Healthcare Share Price Update
Zydus Lifesciences Ltd. share price moved up by 1.66% from its previous close of Rs 1,087.60. Zydus Lifesciences Ltd. stock last traded price is 1,105.60
Share Price Value
Today/Current/Last 1,105.601,106.10
Previous Day 1,087.601,087.45

Found Insights useful?

Cadila Healthcare Share Price Returns

1 Day	1.66%
1 Month	17.61%
3 Months	19.77%
1 Year	12.61%
3 Years	117.75%
5 Years	69.92%

Cadila Healthcare Share Recommendations

Mean recosCurrent

HOLD

29 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	5	5	5	5
Buy	9	9	5	5
Hold	10	10	11	11
Sell	3	3	5	5
Strong Sell	2	2	2	2
# Analysts	29	29	28	28

Recent Recos

Target₹1090
OrganizationJM Financial
HOLD

Target₹1078
OrganizationSharekhan by BNP Paribas
BUY

Target₹1196
OrganizationGeojit Financial Services
ACCUMULATE

View all Stock Recommendations

News & Analysis

View all Cadila Healthcare Share News & Announcements

Financials

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	6,975.90	6,232.20	6,728.60	6,608.50	5,326.60
Total Income Growth (%)	11.93	-7.38	1.82	24.07	0.40
Total Expenses	5,492.60	4,443.50	4,723.30	4,859.90	4,110.50
Total Expenses Growth (%)	23.61	-5.92	-2.81	18.23	2.53
EBIT	1,483.30	1,788.70	2,005.30	1,748.60	1,216.10
EBIT Growth (%)	-17.07	-10.80	14.68	43.79	-6.17
Profit after Tax (PAT)	1,042.10	1,258.60	1,466.80	1,170.90	1,026.20
PAT Growth (%)	-17.20	-14.19	25.27	14.10	11.52
EBIT Margin (%)	21.26	28.70	29.80	26.46	22.83
Net Profit Margin (%)	14.94	20.20	21.80	17.72	19.27
Basic EPS (₹)	10.36	12.51	14.58	11.64	10.17

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	2,757.40	3,412.70	2,745.40	6,005.00	2,593.40
Total Income Growth (%)	-19.20	24.31	-54.28	131.55	-12.01
Total Expenses	2,289.00	1,855.30	2,132.90	2,174.90	1,999.00
Total Expenses Growth (%)	23.38	-13.02	-1.93	8.80	10.31
EBIT	468.40	1,557.40	612.50	3,830.10	594.40
EBIT Growth (%)	-69.92	154.27	-84.01	544.36	-47.64
Profit after Tax (PAT)	296.50	1,156.60	384.70	2,813.70	470.60
PAT Growth (%)	-74.36	200.65	-86.33	497.90	-40.42
EBIT Margin (%)	16.99	45.64	22.31	63.78	22.92
Net Profit Margin (%)	10.75	33.89	14.01	46.86	18.15
Basic EPS (₹)	2.95	11.49	3.82	27.96	4.68

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	23,511.00	19,831.50	17,424.00	15,489.90	14,449.10
Total Revenue Growth (%)	18.55	13.82	12.49	7.20	0.57
Total Expenses	17,264.70	15,008.40	14,230.10	12,764.50	11,844.80
Total Expenses Growth (%)	15.03	5.47	11.48	7.76	-5.30
Profit after Tax (PAT)	4,525.50	3,859.50	1,960.30	4,487.30	2,133.60
PAT Growth (%)	17.26	96.88	-56.31	110.32	81.34
Operating Profit Margin (%)	27.58	25.08	19.28	18.68	19.18
Net Profit Margin (%)	19.47	19.74	11.37	29.39	14.81
Basic EPS (₹)	44.97	38.14	19.30	43.83	20.84

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	15,812.50	11,903.50	9,280.00	8,160.60	7,869.30
Total Revenue Growth (%)	32.84	28.27	13.72	3.70	9.34
Total Expenses	8,367.80	7,655.10	7,044.00	6,677.40	5,993.30
Total Expenses Growth (%)	9.31	8.68	5.49	11.41	7.27
Profit after Tax (PAT)	5,774.90	3,441.50	1,529.20	857.90	1,476.20
PAT Growth (%)	67.80	125.05	78.25	-41.88	4.48
Operating Profit Margin (%)	52.31	42.88	28.79	20.27	25.02
Net Profit Margin (%)	38.20	31.81	17.51	10.74	18.97
Basic EPS (₹)	57.39	34.01	15.06	8.38	14.42

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 1.62% of its operating revenues towards interest expenses and 16.27% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	37,201.70	29,280.80	25,756.40	27,795.40	23,884.70
Total Assets Growth (%)	27.05	13.68	-7.34	16.37	0.84
Total Liabilities	10,843.30	7,179.20	6,068.10	8,741.60	8,955.10
Total Liabilities Growth (%)	51.04	18.31	-30.58	-2.38	-25.23
Total Equity	26,358.40	22,101.60	19,688.30	19,053.80	14,929.60
Total Equity Growth (%)	19.26	12.26	3.33	27.62	27.49
Current Ratio (x)	1.89	2.15	1.81	1.56	1.11
Total Debt to Equity (x)	0.13	0.04	0.07	0.25	0.35
Contingent Liabilities	1,428.00	1,277.10	1,315.20	1,210.70	1,295.50

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	32,316.90	24,084.80	20,563.60	17,740.00	18,463.60
Total Assets Growth (%)	34.18	17.12	15.92	-3.92	11.55
Total Liabilities	11,126.80	8,368.30	6,924.20	4,499.50	5,719.10
Total Liabilities Growth (%)	32.96	20.86	53.89	-21.33	8.08
Total Equity	21,190.10	15,716.50	13,639.40	13,240.50	12,744.50
Total Equity Growth (%)	34.83	15.23	3.01	3.89	13.18
Current Ratio (x)	1.95	3.12	2.57	1.70	1.25
Total Debt to Equity (x)	0.39	0.39	0.35	0.20	0.31
Contingent Liabilities	1,737.70	1,750.30	752.40	2,233.10	2,009.30

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	6,776.70	3,227.90	2,688.80	2,104.10	3,293.90
Net Cash used in Investing Activities	-8,372.30	-1,475.20	1,171.20	1,154.40	-724.60
Net Cash flow from Financing Activities	2,014.20	-1,810.40	-4,400.40	-868.30	-2,547.70
Net Cash Flow	413.80	-74.80	-533.80	2,372.90	-90.50
Closing Cash & Cash Equivalent	826.80	413.00	573.10	3,460.10	1,087.20
Closing Cash & Cash Equivalent Growth (%)	100.19	-27.94	-83.44	218.26	-7.68
Total Debt/ CFO (x)	0.47	0.24	0.43	1.99	1.39

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	3,114.00	1,999.10	1,078.20	1,310.70	2,225.30
Net Cash used in Investing Activities	-4,503.60	-1,830.60	-1,959.70	768.20	-2,713.80
Net Cash flow from Financing Activities	1,384.50	-300.80	827.00	-1,709.80	257.20
Net Cash Flow	-5.10	-132.30	-54.50	369.10	-231.30
Closing Cash & Cash Equivalent	103.00	108.10	248.10	523.10	154.00
Closing Cash & Cash Equivalent Growth (%)	-4.72	-56.43	-52.57	239.68	-60.03
Total Debt/ CFO (x)	2.68	3.09	4.47	2.03	1.76

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 2116.6 cr is 0.42 times compared to the reported net profit of Rs 5040.0 cr. (Source: Consolidated Financials)
Decrease in Cash from Investing
Company has used Rs 8296.1 cr for investing activities which is an YoY decrease of 0.91%. (Source: Consolidated Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	18.89	19.46	11.19	26.39	16.42
Return on Capital Employed (%)	22.77	20.48	16.43	14.29	17.24
Return on Assets (%)	12.16	13.18	7.61	16.14	8.93
Interest Coverage Ratio (x)	44.17	69.81	31.15	28.07	21.62
Asset Turnover Ratio (x)	0.70	0.71	0.64	0.38	0.37
Price to Earnings (x)	19.72	26.25	25.38	7.96	21.19
Price to Book (x)	3.72	5.10	2.84	2.10	3.47
EV/EBITDA (x)	12.52	18.18	12.97	11.46	14.79
EBITDA Margin (%)	31.52	28.99	23.47	23.35	23.83

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	27.25	21.89	11.21	6.47	11.58
Return on Capital Employed (%)	32.32	21.53	14.14	11.80	14.27
Return on Assets (%)	17.86	14.28	7.43	4.83	7.99
Interest Coverage Ratio (x)	18.18	13.16	10.79	15.54	33.82
Asset Turnover Ratio (x)	0.54	0.48	0.46	0.44	0.44
Price to Earnings (x)	15.43	29.41	32.57	41.67	30.58
Price to Book (x)	4.20	6.43	3.65	2.70	3.54
EV/EBITDA (x)	11.54	20.78	18.09	18.15	20.39
EBITDA Margin (%)	55.78	47.54	34.39	26.26	30.82

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
Stochastic Crossover
Bearish signal on weekly chart
Appeared on: 5 Jun 2026
Region: Overbought (Above 80)
Last Signal 30 Apr 2026 (Loss 0.14%)
Average price decline of -6.44% within 7 weeks of Bearish signal in last 10 years
Price Analysis
45%
Positive Movement
since 1st Jan 2005
on basis
55%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 1115.90 Pivot
1100.70
S1 1090.40
R2 1126.20 S2 1075.20
R3 1151.70 S3 1049.70
Average True Range
5 Days 14 Days 28 Days
27.37 28.53 26.81

Found Technicals useful?

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Cadila Healthcare	22.07	3.76	18.58	20.64	9.61	16.47	27.90	18.51	50.09	1.27	0.43	5.56
Torrent Pharma	69.99	8.61	25.78	9.30	4.88	12.70	23.93	15.29	63.92	1.13	1.76	4.90
Cipla	28.66	3.22	11.26	15.65	9.12	7.65	19.72	13.74	48.03	3.44	0.01	0.07
Dr. Reddys	25.23	2.77	11.07	13.90	7.21	10.76	17.07	12.29	50.41	1.80	0.17	1.11
Lupin	19.41	4.60	23.75	30.58	13.90	19.09	28.13	19.15	116.75	1.90	0.26	0.78
Add More

Annual Ratios (%)

Choose from Peers

Mankind Pharma
Aurobindo Pharma
Laurus Labs
Biocon
Alkem Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Found Peer Comparison useful?

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 75,46,25,314 75.00 % 0.00
Pledge 0 0.00 % 0.00
FII 6,98,85,360 6.94 % -0.11
DII 11,23,92,336 11.17 % 0.10
MF 4,90,65,382 4.88 % 0.16
Others 6,93,30,980 6.89 % 0.01
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 75.00 75.00 74.99 74.99
Pledge 0.00 0.00 0.00 0.00
FII 6.94 7.06 7.34 7.13
DII 11.17 11.06 10.84 11.09
Mutual Funds 4.88 4.71 4.70 5.56
Others 6.89 6.87 6.82 6.79

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Parag Parikh Flexi Cap Direct-G
Equity: Flexi Cap
5
- 1,712.50
  Amount Invested (in Cr.)
- 1.21497542%
  % of AUM
- 1.84
  % Change (MoM basis)
Kotak Flexicap Direct-G
Equity: Flexi Cap
3
- 936.50
  Amount Invested (in Cr.)
- 1.71%
  % of AUM
- 0.00
  % Change (MoM basis)
ICICI Pru Large Cap Direct-G
Equity: Large Cap
5
- 287.92
  Amount Invested (in Cr.)
- 0.3805936%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Cadila Healthcare Futures & Options

Type
Expiry Month
Strike Price

Date	Price	Open Interest
30-06-2026Current	26.406.35 (31.67%)	1,62,00034,200 (26.76%)
21.00 Open	29.25 High	20.35 Low
20.05 Close	654 Contracts Traded	6,691.44 Turnover (₹ Lakhs)

Open Interest as of 09 Jun 2026

Expiry MonthPlease select expiry month:

Date	Price	Open Interest
30-06-2026Current	1,112.7019.50 (1.78%)	1,07,28,9001,44,900 (1.37%)
1,093.00 Open	1,116.30 High	1,093.00 Low
1,093.20 Prev Close	2,021 Contracts Traded	20,200.61 Turnover (₹ Lakhs)

Open Interest as of 09 Jun 2026

Cadila Healthcare Top Searches

Corporate Actions

Recent
General Meeting
-
May 20, 2026
General Meeting
Buy Back of Shares
May 19, 2026
General Meeting
Buy Back of Shares
May 19, 2026

Announced on	Meeting on
May 13, 2026	May 19, 2026
Audited Results, Dividend & Buy Back
Jan 27, 2026	Feb 09, 2026
Quarterly Results
Nov 03, 2025	Nov 06, 2025
Quarterly Results & Fund raising
Aug 01, 2025	Aug 12, 2025
Quarterly Results
May 09, 2025	May 20, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 19, 2026 Jul 24, 2026 100%
May 20, 2025 Jul 25, 2025 1100%
May 17, 2024 Jul 26, 2024 300%
May 18, 2023 Jul 28, 2023 600%
May 20, 2022 Jul 28, 2022 250%
Bonus
Announced on Ex-Date
Feb 25, 2010 Apr 05, 2010
Bonus Ratio: 1 share(s) for every 2 shares held
Apr 28, 2006 Aug 30, 2006
Bonus Ratio: 1 share(s) for every 1 shares held
Splits
Announced on Ex-Date
Aug 12, 2015 Oct 06, 2015
Split: Old FV5.0| New FV:1.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
May 20, 2026 Aug 11, 2026
-
May 19, 2026 -
Buy Back of Shares
May 19, 2026 -
Buy Back of Shares
May 19, 2026 -
Buy Back of Shares
May 19, 2026 -
Buy Back of Shares

About Cadila Healthcare

Zydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 1,11,249.23 Crore) operating in Pharmaceuticals sector.

Zydus Lifesciences Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 7,721.20 Crore, up 10.68 % from last quarter Total Income of Rs 6,975.90 Crore and up 16.84 % from last year same quarter Total Income of Rs 6,608.50 Crore. Company has reported net profit after tax of Rs 1,341.30 Crore in latest quarter.

The company’s top management includes Mr.Pankaj R Patel, Dr.Sharvil P Patel, Mr.Ganesh N Nayak, Mr.Mukesh M Patel, Ms.Apurva S Diwanji, Mr.Bhadresh K Shah, Mr.Monappa Arun Akhil, Ms.Shelina P Parikh, Mrs.Upasana K Konidela, Mr.Nitin D Parekh, Mr.Dhaval N Soni. Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-03-2026, the company has a total of 100.62 Crore shares outstanding.

Cadila Healthcare Share Price Today is Rs. 1105.60. On previous day, the Cadila Healthcare Share Price (NSE) closed at Rs. 1087.6, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 75.0% of the stake in Cadila Healthcare shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Cadila Healthcare stocks was 6.95% as compared to 7.06% in Dec 2025 with decrease of 0.11%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 11.17% as compared to 11.06% in Dec 2025 with increase of 0.11%. Out of the total DII holdings in Cadila Healthcare shares 4.88% was held by mutual funds. The rest including public held is 6.88%. Cadila Healthcare stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Cadila Healthcare Dividend: Ever since 1995, Cadila Healthcare dividends has been paid out around 28 times. As on 09 Jun, 2026, 03:58 PM IST, The overall dividend yield for Cadila Healthcare stands at 0.09%. The last dividend paid was on July 24, 2026 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 50.09.

Cadila Healthcare Bonus: The most recent bonus issue had been in year April 5, 2010 around 16 years ago at 2 : 1 ratio. The first bonus issue was announced in Apr 2006.

Stock Forecast:
After showing 7873.8 Cr. of sales and 11.53% of quarterly net profit, there have been multiple ups and downs in the Cadila Healthcare stock prices in the past few weeks. For example, Cadila Healthcare stock price on 2nd of June 2026 was around Rs. 1078.3. Cadila Healthcare share price now stands at an average of Rs. 1105.60. Judging by last week's performance, stock is in up trend.

Cadila Healthcare has a median target price of Rs. 1075.04 in 12 months by 28 analysts. They have provided a high estimate of Rs. 1311.0 and low estimate of Rs. 800.0 for Cadila Healthcare share.

Historical Prices and Performance:
Cadila Healthcare, incorporated in 1995 is a Large Cap company (with a market cap of Rs. 111249.23) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Cadila Healthcare stock was 18.58%, 18.89%, 19.46%, 11.19% and 26.39% respectively.
The Cadila Healthcare share gave a 3 year return of 117.74% as compared to Nifty 50 which gave a return of 25.2%.
Cadila Healthcare announced 100.0% final dividend on July 24, 2026.

Key Metrics:
PE Ratio of Cadila Healthcare is 21.71
Prices/Sales Ratio of Cadila Healthcare is 3.23
Price/Book Ratio of Cadila Healthcare is 3.7

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Cadila Healthcare, major competitors and peers include Torrent Pharma, Cipla, Dr. Reddys and Lupin. As of Dec 2025, the dividend yield of Cadila Healthcare stands at 0.09% while Torrent Pharma, Cipla, Dr. Reddys and Lupin stand at 0.85%, 0.94%, 0.63% and 0.79% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 21.71 and 3.7 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 29, Three months ago this number stood at 28. Out of total, 5 analyst have a'Strong Buy' reco, 9 analyst have a'Buy' reco, 10 analyst have a'Hold' reco, 3 analyst have a'Sell' reco.

Mean recommendations by 29 analyst stand at'Buy'.

Leadership of Cadila Healthcare :
Dhaval N Soni is Co. Secretary & Compl. Officer
Nitin D Parekh is Chief Financial Officer
Pankaj R Patel is Chairman
Sharvil P Patel is Managing Director
Ganesh N Nayak is Executive Director
Mukesh M Patel is Non Executive Director
Bhadresh K Shah is Independent Director
Apurva S Diwanji is Independent Director
Monappa Arun Akhil is Independent Director
Upasana K Konidela is Independent Woman Director
Shelina P Parikh is Independent Woman Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty Next 50, Nifty 100, Nifty 200, Nifty 500, BSE 500

Address

Zydus Corporate Park, Scheme No.63,Survey No. 536,Khoraj (Gandhinagar),Ahmedabad, Gujarat - 382481

Contact

investor.grievance@zyduscadila.com

http://www.zyduslife.com

Executive Leadership

PR

Pankaj R Patel

Chairman

SP

Sharvil P Patel

Managing Director

GN

Ganesh N Nayak

Executive Director

MM

Mukesh M Patel

Non Executive Director

Show More

Auditors

Deloitte Haskins & Sells LLP

FAQs about Cadila Healthcare share

1. What's the Cadila Healthcare share price today?
Cadila Healthcare share price is Rs 1,105.60 as on 09 Jun, 2026, 03:58 PM IST. Cadila Healthcare share price is up by 1.66% based on previous share price of Rs. 1087.6.
2. What is Cadila Healthcare's 52 week high / low?
52 Week high of Cadila Healthcare share is Rs 1,115.50 while 52 week low is Rs 835.50
3. What is the market cap of Cadila Healthcare?
Within the Pharmaceuticals sector, Cadila Healthcare stock has a market cap rank of 4. Cadila Healthcare has a market cap of Rs 1,11,249 Cr.
4. What are the returns for Cadila Healthcare share?
Return Performance of Cadila Healthcare Shares:
- 1 Week: Cadila Healthcare share price moved up by 2.69%
5. What is the PE & PB ratio of Cadila Healthcare?
The PE ratio of Cadila Healthcare stands at 22.07, while the PB ratio is 3.76.

Top Gainers

As on 03:43 PM | 09 Jun 2026

Data Patterns (India)

4,558.50

417.20 (10.08%)

3,417.70

252.50 (7.98%)

2,866.40

185.60 (6.93%)

2,255.20

144.20 (6.84%)

5,835.00

362.00 (6.62%)

Top Losers

As on 03:59 PM | 09 Jun 2026

Tata Technologies

745.10

-34.50 (-4.43%)

1,097.80

-45.11 (-3.95%)

107.62

-3.47 (-3.13%)

Krishna Instt of Medical Sciences

781.60

-19.61 (-2.45%)

Balrampur Chini

536.95

-13.45 (-2.45%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.